^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P1 agonist

    Related drugs:
    2d
    A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Dec 2027
    Trial initiation date
    |
    RAS mutation
    |
    cytarabine
    17d
    Clad'Action: Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis (clinicaltrials.gov)
    P=N/A, N=77, Completed, University Hospital, Rouen | Recruiting --> Completed
    Trial completion
    |
    IFNB1 (Interferon Beta 1)
    28d
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)
    2ms
    Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)
    4ms
    Cladribine Venetoclax in Monocytic AML (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Colorado, Denver | N=40 --> 20
    Enrollment change
    |
    Venclexta (venetoclax)
    6ms
    ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=204, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting
    Enrollment closed • HEOR
    6ms
    DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
    P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial completion date: Sep 2030 --> Jul 2027
    Trial completion date
    |
    Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
    6ms
    Hairy Cell Leukemia Diagnosed by Flow Cytometry Despite Absence of Hairy Cells in Peripheral Blood: A Case Report. (PubMed, Cureus)
    The patient was treated with cladribine and rituximab and achieved hematological recovery. This case highlights the usefulness of FCM for the diagnosis of HCL in the presence of splenomegaly, pancytopenia, and myelofibrosis, even though hairy cells may be absent in peripheral blood.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CD20 (Membrane Spanning 4-Domains A1) • IL2RA (Interleukin 2 receptor, alpha) • ITGAX (Integrin Subunit Alpha X) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    BRAF V600E • BRAF V600 • CD20 positive
    |
    Rituxan (rituximab) • cladribine
    7ms
    Intercurrent presentation of hairy cell leukemia and diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis: a case report. (PubMed, Leuk Res Rep)
    Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoma that is highly responsive to the purine analog cladribine...Further research is needed to better understand the pathophysiological links between HCL, large cell transformation, and HLH. Additionally, registry or other cross-sectional studies with larger numbers of HCL patients could clarify the exact frequency of these rare but fatal complications.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    cladribine
    8ms
    CD103-Negative Hairy Cell Leukemia: A Case Report From University Teaching Hospital, Zambia. (PubMed, Case Rep Med)
    For a disease that is more prevalent in Caucasians and less common in African populations, we report an unusual case of CD103-negative classical HCL in a 43-year-old African male, who presented with refractory anemia, thrombocytopenia, and splenomegaly. In patients with refractory anemia, it is crucial to consider investigating HCL, as this may influence therapeutic decisions and, consequently, overall patient outcomes.
    Journal
    |
    ITGAE (Integrin Subunit Alpha E)
    |
    cladribine
    8ms
    A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cytarabine